TOP PAGE
ENGLISH
JAPANESE
|
CONNECT WITH US:
Home
About
Services
Contact
Log in
*
Home
Press release
Jan 14, 2021 09:40 JST
Source:
Antengene
花旗首次覆蓋德琪醫藥(6996.HK),給予「買入」評級,目標價32.80港元
香港, Jan 14, 2021 - (ACN Newswire) - 花旗於昨天(12日)發表研報,首次覆蓋德琪醫藥(6996.HK),給予「買入」評級,目標價32.80港元,較13日的收市價具有約88.1%溢價空間。
花旗表示德琪醫藥是一家短期內具前景的擁有低風險資產的臨床階段生物製藥公司。該公司成功驗證了SINE化合物的治療潛力,並在2018年5月獲得了Karyopharm的獨家許可能夠在亞太地區開發和商業化三種SINE化合物- ATG-010 (selinexor), ATG-016 (eltanexor)以及ATG-527 (verdinexor)。ATG-010 (selinexor)是首款及唯一一款獲FDA批准的針對XPO1的可同時用於治療復發/難治性多發性骨髓瘤及復發/難治性瀰漫大B細胞淋巴瘤的藥物。花旗認為,FDA的批准驗證了XPO1成為可成藥的靶點以及SINE化合物成為新型藥物。這將支持德琪醫藥較低風險的短期商業化前景。該行相信,如果藥物能夠在中國成功上市,將成為中國生物製藥公司的關注焦點。
花旗相信,德琪醫藥採用的「聯用、互補」研發策略能夠優化其資產的臨床收益,並最大化其商業潛力。除了SINE產品組合外,德琪醫藥還擁有其他9種協同的管線產品,針對多種癌症治療作用機制。此外,德琪醫藥正在亞太地區積極探索組合療法的潛力以及具有更高患病率的新適應症。這為該行看好德琪醫藥的前景給予有力支持。
關於德琪醫藥有限公司
德琪醫藥有限公司是一家專注於創新抗腫瘤藥物的亞太地區臨床階段生物製藥公司,旨在為亞太地區及全球各地的患者提供全新作用機制的抗腫瘤創新療法。自成立以來,德琪醫藥已建立起擁有12款臨床及臨床前創新藥物的豐富產品管線,並在亞太地區取得11個臨床試驗批件。德琪人以「醫者無疆,創新永續」為願景,力爭通過對全球首創和同類最優的專研與市場化,解決亞太乃至全球患者未滿足的臨床需求。
此新聞稿由博達浩華國際財經傳訊集團發佈。如有垂詢,請聯絡:
博達浩華國際財經傳訊集團
李耀榮先生 +852 3150 6707
bunny.lee@pordahavas.com
史辛夷小姐 +852 3150 6778
angela.shi@pordahavas.com
陳曼莉小姐 +852 3150 6721
mandy.chen@pordahavas.com
Source: Antengene
Sectors: Daily Finance, Daily News, BioTech, Healthcare & Pharm
Copyright ©2024 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
Related Press Release
Antengene Corporation Successfully Listed on Main Board of SEHK
November 20 2020 15:15 JST
Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization
July 20 2020 08:05 JST
More Press release >>
Latest Press Release
Mazda Production and Sales Results for March 2024 and for April 2023 through March 2024
Apr 25, 2024 18:21 JST
MHI Begins Operation of SOEC Test Module the Next-Generation High-Efficiency Hydrogen Production Technology at Takasago Hydrogen Park
Apr 25, 2024 17:45 JST
GAC Honda to Begin Sales of All-new e:NP2, the Second Model of e:N Series
Apr 25, 2024 16:50 JST
Toyota Exhibiting at Beijing Motor Show 2024
Apr 25, 2024 16:25 JST
Honda Reaches Basic Agreement with Asahi Kasei on Collaboration for Production of Battery Separators for Automotive Batteries in Canada
Apr 25, 2024 11:10 JST
UNIQLO Sponsors KAWS + Warhol Exhibition Tour, Starting in Pittsburgh
Apr 25, 2024 09:00 JST
Mitsubishi Power Begins Commercial Operation of Seventh M701JAC Gas Turbine in Thailand GTCC Project; Achieves 75,000 AOH To-Date
Apr 24, 2024 17:19 JST
MC and Denka Sign J/V Agreement in Fullerene Business
Apr 24, 2024 17:02 JST
Mitsubishi Motors Posts Record Sales in the Philippines in FY2023
Apr 24, 2024 13:56 JST
NEC Develops High-speed Generative AI Large Language Models (LLM) with World-class Performance
Apr 24, 2024 13:25 JST
Fujitsu SX Survey reveals key success factors for sustainability
Apr 23, 2024 10:25 JST
Fujitsu and METRON collaborate to drive ESG success: slashing energy costs, boosting productivity with new manufacturing industry solutions
Apr 22, 2024 16:09 JST
NEC Strengthens Commitment to Space Industry with Investment in Seraphim Space Venture Fund II
Apr 22, 2024 15:09 JST
Soft Space Launches the First and Only JCB Payment Gateway in Malaysia
Apr 22, 2024 15:00 JST
TOYOTA GAZOO Racing takes a one-two in Croatian thriller
Apr 22, 2024 10:47 JST
First-ever Mazda CX-80 Crossover SUV Unveiled in Europe
Apr 19, 2024 13:50 JST
Fujitsu develops technology to convert corporate digital identity credentials, enabling participation of non-European companies in European data spaces
Apr 19, 2024 10:17 JST
Mitsubishi Heavy Industries and NGK to Jointly Develop Hydrogen Purification System from Ammonia Cracking Gas
Apr 18, 2024 17:01 JST
Toyota Launches All-New Land Cruiser "250" Series in Japan
Apr 18, 2024 13:39 JST
Fujitsu and Oracle collaborate to deliver sovereign cloud and AI capabilities in Japan
Apr 18, 2024 11:14 JST
More Latest Release >>